Latest News - Business of Medicine

Monday, March 05, 2018

American Academy of Neurology Praised for New Neutral Stance on Lawful Physician-Hastened Death

The American Academy of Neurology (AAN) received praise for a new position statement published in late February 2018 that rescinds the AAN 1998 position against medically-assisted suicide, or law…

Read the full story

Thursday, March 01, 2018

Biosimilar Being Developed for Botox

In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on the development and commerc…

Read the full story

Tuesday, August 29, 2017

AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent

AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s…

Read the full story

Monday, November 23, 2015

Pfizer and Allergan to Combine

The boards of directors for Pfizer Inc. and Allergan plc have both unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allerga…

Read the full story

Wednesday, October 28, 2015

Global Multiple Sclerosis Therapeutics Market Expected to Reach $20 Billion by 2024

The global therapeutics market over the next decade for MS is expected to swell to $20 billion at a compound annual growth rate of 1.5 percent, according to a new report. The recently published “Epi…

Read the full story

Thursday, August 21, 2014

Vicodin vex: DEA tightens restrictions on hydrocodone combos

On Friday the US Drug Enforcement Administration (DEA) will move hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II. Pure hydrocodone drugs have been list…

Read the full story